In Partnership With
In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.
0:04 - Intro
0:39 - Prostate Cancer Screening Recommendations
3:45 - Prior Guidelines
4:23 - Role of PSA Testing
6:50 - Imaging in Prostate Cancer
8:56 - Genetics
10:38 - Available Treatment Options
12:40 - Newer Therapeutics
16:03 - Minimally Invasive & Robotic Assistant Surgical Techniques
18:55 - Personalized Treatments
21:40 - Looking Forward
In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, president of the Allina Health Cancer Institute and the chief academic officer for Allina Health, delves into the critical topic of prostate cancer screening, particularly for men within a community setting, and discusses some of the recent advancements in the prostate cancer space.
Prostate cancer remains one of the most common cancers among men, leaving many navigating a complex array of decisions regarding screening, treatment, and new advancements. Here, Konety unpacks the latest recommendations, acknowledging the evolving role of the prostate-specific antigen (PSA) test. However, he also acknowledges recognizes its limitations, noting how the use of additional tests may improve accuracy and reduce unnecessary procedures, as well as leveraging MRI.
“PSA still seems to be the bedrock of prostate cancer screening. It's not a great marker, but it is perhaps the best cancer specific marker out there in terms of blood tests,” Konety explains. “MRI is definitely a great adjunct to follow patients who have an elevated PSA and a negative biopsy to better stage the cancer. It's becoming a valuable tool, 1 to guide where to biopsy, but also [to] guide the decision making around whether to biopsy.”
Konety also provides a valuable overview of the treatment landscape, outlining the range of options available for prostate cancer patients. He emphasizes the importance of tailoring treatment based on individual factors, and provides valuable insights into the considerations made when choosing between treatment approaches.
“Now that we're understanding the multidimensionality of cancer and how it can express itself, we're able to better tailor the treatments,” Konety explains.
In addition, the episode explores the impact of minimally invasive and robotic-assisted surgical techniques on both treatment efficacy and accessibility within community settings. Konety discusses the advantages these advancements offer, including potentially improved outcomes, highlighting the possibility for wider access to cutting-edge therapies.
Konety's expertise shines throughout the conversation, offering listeners a comprehensive understanding of the current state of prostate cancer care.
Capivasertib Improves PFS in PTEN-Deficient mHSPC
November 30th 2024Data from the phase 3 CAPItello-281 trial showed that capivasertib plus abiraterone and androgen deprivation therapy significantly improved radiographic progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
